Welcome to our ninth annual report on US securities class actions filed against publicly traded life sciences companies, which include pharmaceutical, biotechnology, medical device, and healthcare companies.
In the following sections, we analyze data and trends in securities class actions across all industries and in the life sciences industry in particular. We then highlight important 2024 decisions issued by federal courts in securities cases brought against life sciences companies and their officers.
Read the full report here.
The post Securities Litigation Against Life Sciences Companies 2024 Year in Review appeared first on Life Sciences Perspectives.